Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 188,800 shares, a drop of 23.8% from the February 28th total of 247,700 shares. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 0.5 days. Currently, 4.7% of the company’s shares are short sold.

Dermata Therapeutics Price Performance

NASDAQ DRMA traded down $0.02 on Tuesday, hitting $1.06. 54,243 shares of the company were exchanged, compared to its average volume of 1,133,290. Dermata Therapeutics has a twelve month low of $1.00 and a twelve month high of $6.67. The company’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.30. The firm has a market capitalization of $5.76 million, a P/E ratio of -0.07 and a beta of 0.65.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.